An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers
Latest Information Update: 26 May 2024
At a glance
- Drugs Dabigatran etexilate (Primary) ; Selpercatinib (Primary)
- Indications CNS cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 15 Jul 2021 Status changed from active, no longer recruiting to completed.
- 18 May 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2021 Status changed from not yet recruiting to recruiting.